<?xml version="1.0" encoding="UTF-8"?>
<p>T cell responses in survivors of EVD epidemics has been relatively well studied. Four patients with acute EVD demonstrated CD8+ and CD4+ T cell activation against several viral proteins, and this activation persisted for up to one month after infection [
 <xref rid="pntd.0006530.ref017" ref-type="bibr">17</xref>]. Consistent with this study, prolonged T cell activation was observed in a single patient who cleared EBOV infection without the use of experimental drugs [
 <xref rid="pntd.0006530.ref027" ref-type="bibr">27</xref>]. Another study evaluating patients during the acute phase of infection, demonstrated that survivors have T cells that express lower levels of the inhibitory molecules CTLA-4 and PD-1, compared to fatal EVD cases with high viral load [
 <xref rid="pntd.0006530.ref020" ref-type="bibr">20</xref>]. Additionally, a study of SUDV survivors, 12 years post infection, demonstrated strong memory CD4+, but not CD8+, T cell activation and neutralizing humoral immunity [
 <xref rid="pntd.0006530.ref028" ref-type="bibr">28</xref>]. Whole irradiated SUDV was used to stimulate PBMC samples in these long-recovered survivors, likely contributing to the limited CD8+ activation.
</p>
